We analysed the chronic effects of the peroxisome proliferator-activated receptor b/d (PPAR-b) agonist GW0742 on the renin-independent hypertension induced by deoxycorticosterone acetate (DOCA)-salt.
Introduction
Hypertension is a well-established risk factor for the development of atherosclerosis. The inactivation of nitric oxide (NO) by vascular superoxide anion (O 2 †2
) plays a critical role in the pathogenesis of cardiovascular diseases, including hypertension. 1 Arterial O 2 †2 is elevated in angiotensin II (Ang II)-induced hypertension, attributable to a large extent to nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation by Ang II. 2, 3 However, an excess of vascular O 2 †2 production has also been found in deoxycorticosterone acetate (DOCA)-salt hypertension, 4 -6 a model with a markedly depressed renin-Ang system because of sodium retention. 7 Patients with low renin (i.e. saltsensitive hypertension) represent 30% of the essential hypertensives and show a poor therapeutic response to Ang-converting enzyme inhibitors and Ang receptor blockers. Endothelin-1 (ET-1) has been shown to contribute to the pathogenesis of salt-sensitive hypertension secondary to a low-renin state in animals and humans. 8, 9 This is, at least in part, due to vascular O 2 †2 production via the ET A /NADPH oxidase pathway 10 leading to the endothelial dysfunction.
Peroxisome proliferator-activated receptors (PPARs) are ligandactivated transcription factors that belong to the nuclear hormone receptor superfamily, which heterodimerize with the retinoid X receptor to regulate the transcription of diverse genes. 11 There are three isotypes of PPARs: PPARa, PPARb/d (PPARb), and PPARg. Their role on lipid and glucose metabolism is well known. 12 In addition, PPARa and PPARg activators prevent hypertension, cardiac fibrosis, vascular hypertrophic remodelling, endothelial dysfunction, and renal injury in DOCAsalt rats, 13 -18 while the effects of PPARb activators are unknown. These protective effects seem to be associated with a decreased ET-1 production, 13 -16,18 by inhibiting the activator protein-1 signalling pathway. 19, 20 Recently, it has been found that PPARa and PPARg ligands also inhibit the ET-1 pathway to induce both vascular proinflammatory effects 21 and cardiac hypertrophy. 22, 23 The activation of PPARb also exhibits anti-inflammatory properties in the vessel wall. 24 Moreover, the oral administration of PPARb agonist GW0742 reduces atherosclerosis in the LDL receptor knockout (LDLR 2/2 ) mice, 25 and substantially attenuates Ang II-accelerated atherosclerosis and the associated arterial inflammatory and atherosclerotic gene expression. 26 Recently, we found that GW0742 reduced blood pressure, improved the endothelial dysfunction, and reduced vascular proinflammatory and proaterogenic status in spontaneously hypertensive (SHR) by interfering with the Ang II signalling pathway, through up-regulation of the regulators of G-proteincoupled signalling proteins (RGS): RGS4 and RGS5. 27 RGS proteins play important roles in the regulation of G protein-coupled receptor signalling by binding to the active G subunits and stimulating GTP hydrolysis, thus switching off G protein signalling. 28 Moreover, upregulated RGSs induced by PPARb activation was associated with reduced contractions to ET-1. 27 In addition, RGS5 knockdown in intact mesenteric artery increased myogenic tone. 29 PPARb activation also inhibits AP-1 signalling. 30, 31 However, there is no information about the effects of PPARb ligands on ET-1 production and the ET-1 pathway in the vascular system. We hypothesized that GW0742 affects the development of the ET-1-dependent and Ang II-independent hypertension induced by DOCA-salt by interfering with the production of ET-1 and/or its signalling. Therefore, the aim of the present study was to examine whether chronic intake of GW0742 prevents the DOCA-salt-induced hypertension and endothelial dysfunction and, if so, to determine the underlying mechanism, focusing on the involvement of ET-1 and oxidative stress.
Methods
The investigation conforms to the Guide for the Care , mixed in 1 mL of 1% methylcellulose. The vehicle groups only received methylcellulose. Systolic blood pressure (SBP) and heart rate (HR) were measured in conscious, pre-warmed, restrained rats by tail-cuff plethysmography. The cardiac, left ventricular, and renal weight indices were calculated by dividing the heart, left ventricle, and kidney weight by the body weight. Plasma ET-1 levels were determined with the use of a commercially available enzyme-linked immunosorbent assay kit. Descending thoracic aortic rings were mounted in organ baths for isometric tension recording. Reactive oxygen species (ROS) levels were estimated from the ratio of 2 ′ ,7 ′ -dichlorofluorescein (DCF)/4 ′ ,6-diamidino-2-phenylindole (DAPI) and ethidium/DAPI fluorescence in sections of unfixed thoracic aortic rings incubated for 30 min with 2,7 ′ -dichlorofluorescein diacetate or dihydroethidium (DHE) and counterstained with the nuclear stain DAPI. NADPH oxidase activity was measured by the lucigenin-enhanced chemiluminescence assay stimulated by addition of NADPH. Protein and mRNA expression was measured by western blotting analysis and reverse transcriptase-polymerase chain reaction (RT -PCR) analysis, respectively. An expanded Methods section is available in the Supplementary material online.
Results

Effects of GW0742 on blood pressure, morphological variables, and plasma and urinary determinations
Rats receiving DOCA-salt showed a progressive increase in SBP when compared with animals in the control group ( Figure 1A ). This increase was significant (P , 0.05) from the first week, reaching a difference of 44 mmHg at the end of the treatment. Chronic treatment with 5 and 20 mg kg 21 GW0742 prevented, in a dose-dependent manner, the increase in SBP by 61 and 100%, respectively, in DOCA-salttreated rats (P , 0.01), being without effect in control animals. At the end of the experiment, reduced HR ( 9%, P , 0.05 vs. untreated control rats) was also observed in the DOCA-salt group when compared with the control group ( Figure 1B) . This effect was not modified by GW0742.
The increase in body weight (BW) was higher in control than in the DOCA-salt group after 5 weeks (144 + 6 and 100 + 6%, respectively, P , 0.01). This increase was also accompanied by a higher visceral fat weight either in absolute terms or relative to BW. GW0742-treatment did not modify the gain in BW or the visceral fat weight either in the control or in the DOCA-salt group ( Table 1) . These effects of DOCA-salt seem to be related to a lower food intake (26 + 2 and 22 + 2 g day 21 , in the control and DOCA-salt groups, respectively, P , 0.05), which were also unaffected by GW0742. Absolute left ventricle weight (LVW) and LVW relative to BW or to heart weight (HW) and kidney weight (KW) relative to BW were higher in DOCAsalts group when compared with the control group. GW0742 at 20, but not at 5 mg kg 21 , significantly reduced cardiac hypertrophy parameters while KW/BW was unchanged by the drug ( Table 1) .
The plasma levels of MDA (Supplementary material online, Figure  S1A ), a marker of lipid peroxidation induced by ROS, and the 24 h urinary iso-PGF 2a excretion (Supplementary material online, Figure  S1B ), a more specific marker for lipid peroxidation, were increased in DOCA-salt-treated animals when compared with the control group. GW0742 treatment, at 20 mg kg 21 , reduced both MDA concentrations and iso-PGF 2a excretion in DOCA-salt rats.
PPARb agonist in DOCA-salt hypertension
Effects of GW0742 on PPARb and PPARb-target genes in aorta
The gene and protein expression of PPARb was significantly increased in the aorta (Supplementary material online, Figure S2A and S2C) from the DOCA-salt group when compared with control rats. Chronic treatment with GW0742 at both doses restored these changes of PPARb in DOCA-salt to the levels found in the control group. In DOCA-salt aorta the mRNA levels and protein expression of a well-known PPARbtarget gene, PDK4 (Supplementary material online, Figure S2B and S2D) were similar to those found in control rats. As expected, the PPARb agonist significantly increased the mRNA of PDK4 in a dose-dependent manner. Moreover, GW0742 also increased the expression of the fatty acid translocase CD36 dose dependently (Supplementary material online, Figure S3 ).
GW0742 improves the endothelial function in DOCA-salt rats
Aortic rings from DOCA-salt-treated animals showed reduced endothelium-dependent vasodilator responses to acetylcholine in arteries stimulated by phenylephrine when compared with the control aortic rings (E max ¼ 52 + 6 vs. 80 + 5%, respectively, P , 0.01) ( Figure 2A) . GW0742, at 5 mg kg 21 , did not produce a significant increase in the relaxation induced by acetylcholine neither in DOCA-salt rats (E max ¼ 52 + 7%) nor in control rats (E max ¼ 72 + 5%). However, at 20 mg kg 21 GW0742 restored the maximal relaxation to acetylcholine (E max ¼ 81 + 4%) in DOCA-salt to values found in control rats. No differences were observed among groups in the endotheliumindependent vasodilator response to the NO donor sodium nitroprusside in vessels pre-contracted with phenylephrine ( Figure 2B ). Only GW0742, at 20 mg kg 21 , tended to increase the sensitivity to nitroprusside in DOCA-salt rats (pD 2 ¼ 8.26 + 0.10 vs. 8.00 + 0.11, treated and control, respectively, P . 0.05).
Endothelial nitric oxide synthase (eNOS) gene expression in the aorta was similar in all experimental groups ( Figure 2C ). The gene and protein expression of caveolin-1, an allosteric negative regulator of eNOS, was unaltered in DOCA-salt when compared with control rats, but GW0742 at 20 mg kg 21 markedly reduced the expression of caveolin-1 ( Figure 2D and E).
GW0742 reduces vascular ROS levels in DOCA-salt rats by reducing NADPH oxidase activity and by up-regulation of antioxidant genes
Positive red nuclei could be observed in adventitial, medial, and endothelial cells from sections of aorta incubated with DHE ( Figure 3A) . Staining was almost abolished by the O 2 2 scavenger tiron (10 mM), an intracellular O 2 2 scavenger (data not shown), indicating the specificity of this dye for O 2 2 production under the experimental conditions. Nuclear red ethidium fluorescence was quantified and normalized to the blue fluorescence of the nuclear stain DAPI, allowing comparisons between different sections. Rings from DOCA-salt rats showed a marked increased staining in adventitial, medial, and endothelial cells when compared with control rats which was prevented by GW0742 at 20 mg kg 21 ( Figure 3A and B). When we analysed the DCF fluorescence, a peroxidesensitive dye that increased green fluorescence was also observed in aortic rings from DOCA-salt animals. Moreover, both doses of GW0742 reduced DCF staining ( Figure 3C and D) .
NADPH increased lucigenin luminescence in normal aortic rings, which was strongly inhibited (85 + 4%) by previous incubation for 30 min with the flavoprotein inhibitor DPI (10 mM) indicating that external NADPH increased NADPH oxidase activity in vascular tissue. NADPH oxidase activity was increased in aortic rings from DOCA-salt rats when compared with control rats ( Figure 4A ). Chronic treatment with GW0742, at 20 mg kg 21 , reduced significantly this activity in DOCA salt rats, being without effect at 5 mg kg The aortic mRNA levels of antioxidant genes are shown in Supplementary material online, Figure S4 . Cu/Zn-SOD and Mn-SOD were unchanged and catalase was reduced, while GPx1 and HO-1 were increased in DOCA-salt rats when compared with control. The lower dose of GW0742 significantly increased the gene expression of GPx1 and HO-1 in control animals and Mn-SOD and catalase in DOCA-salt rats, whereas the higher dose increased the expression of all antioxidant genes analysed.
Effects of GW0742 on ET-1 synthesis and ET-1 contractile response
ET-1 plays an important role in the endothelial dysfunction seen in mineralocorticoid hypertension, and PPARa and g agonists normalize this dysfunction by improving the abnormal ET-1 system. 13, 14 In order to determine whether there is a relationship between PPARb/d and ET-1 in the vascular wall, we investigated the expression of ppET-1, endothelinconverting enzyme (ECE) 1 and ET A receptor mRNA after GW0742 treatment ( Figure 5 ). As expected, the aortic expression of ppET-1 mRNA was increased in DOCA-salt rats when compared with control rats, without changes in ECE1 or ET A receptor expression. This raise in vascular ppET-1 was accompanied with increased ET-1 plasma levels ( Figure 5C ). Chronic GW0742 treatment, at 5 mg kg 21 , did not modify aortic ppET-1, ECE1, and ET A mRNA, and the ET-1 concentration in plasma in both DOCA-salts and control rats. However, the higher GW0742 dose increases ppET-1 mRNA and reduced ECE1 mRNA in DOCA-salt, without affecting the ET A receptor expression and plasma ET-1 levels.
ET-1 induced sustained contractions in concentration-dependent manners in both the control and DOCA-salt hypertensive rats ( Figure 5E ). The response to ET-1 was significantly decreased in DOCAsalt when compared with control rats. Chronic GW0742 treatment, at 5 mg kg 21 , did not modify this contractile response neither in control nor in DOCA-salt rats, but 20 mg kg 21 reduced this contraction in DOCA-salt rats.
GW0742 increases regulators of G-protein signalling (RGS)-5 expression in aorta
To determine whether PPARb regulates components of vasoactive (such as ET-1) and chemokine receptor signalling we examined the effects of GW0742 on aortic expression of a key regulator of G-protein-coupled receptor signalling, RGS5. Aortic rings from the DOCA-salt group showed a reduced expression of RGS5 ( Figure 5F ), when compared with the normotensive counterparts. GW0742 treatment, at 20 mg kg 21 , increased significantly the expression of RGS5 in the DOCA-salt rats.
3.7 GW0742 improves endothelial function and vascular oxidative stress by PPARb activation, but prevents the increase in SBP independently of PPARb
To determine whether PPARb are involved in the effects induced by GW0742 at 20 mg kg 21 , the PPARb antagonist GSK0660 was administered in addition to GW0742. GSK0660 abolished the effects induced by GW0742 in DOCA-salt aorta on the mRNA levels of PPARb (Supplementary material online, Figure S5A ), and the well-known PPARb-target genes, PDK4 (Supplementary material online, Figure S5B ) and CD36 (Supplementary material online, Figure S5C administered intraperitoneally effectively blunted PPARb in the vasculature. However, GSK0660 did neither modify the development of hypertension induced by DOCA-salt administration nor the effect of GW0742 preventing the increase in SBP ( Figure 6A) , and reducing cardiac hypertrophy parameters (Supplementary material online, Table S2 ) in DOCA-salt rats. In contrast, the increased relaxation to acetylcholine induced by GW0742 in DOCA-salt rats was abolished by GSK0660 ( Figure 6B ). The plasma NOx levels were lower in DOCAsalt when compared with control rats (Supplementary material online, Figure S5D ). GW0742 significantly increased NOx levels in DOCA-salt rats, which was abolished by GSK0660. Furthermore, PPARb blockade suppressed the reduction induced by GW0742 in aortic DHE staining ( Figure 6D ), NADPH oxidase activity ( Figure 6C) , and NOX4 mRNA levels ( Figure 6E) , and the increase induced by GW0742 in the antioxidant genes, Cu/Zn-SOD (Supplementary material online, Figure S5E ), Mn-SOD (Supplementary material online, Figure S5F ), catalase (Supplementary material online, Figure S5G ), GPx1 (Supplementary material online, Figure S5H ), and HO-1 (Supplementary material online, Figure S5I ) expression. GSK0660 did not modify all these parameters in DOCA-salt rats when administered alone. The aortic expression of ppET-1 mRNA, which was increased by GW0742 in DOCA-salt rats, was unaltered by co-administration of GSK0660 ( Figure 6F) . However, the increase in RGS5 mRNA induced by GW0742 was abolished by PPARb blockade ( Figure 6G ). In addition, the contractile response induced by ET-1 was inhibited by GW0742 in both the control and DOCA-salt groups ( Figure 6H ). This inhibitory effect was also suppressed by GSK0660 in DOCA-salt animals.
GW0742 induces relaxant responses in mesenteric arteries in vitro
GW0742 causes, in a concentration-dependent manner (1, 10, 30 mM), a progressive downward shift of the concentration-contractile response curve to phenylephrine (Supplementary material online, Figure S6A ). Cumulative increases in the concentration of GW0742 (10 27 -10 24 M) in small mesenteric arteries previously contracted with phenylephrine also resulted in a concentration-dependent relaxation (IC 50 4.3 + 1.0 mM, Supplementary material online, Figure S6B ). This relaxation was not altered neither by eNOS inhibition with L-NAME nor by incubation with the PPARb antagonist GSK0660.
Discussion
Our experiments provide the first evidence that chronic treatment with the highly selective PPARb agonist GW0742 prevents the increase in SBP, the systemic and vascular oxidative stress, and endothelial dysfunction in salt-sensitive hypertension. These effects, except the changes in SBP, seem to be related to a direct activation of PPARb in the vascular , DOCA-GW5), and DOCA-GW0742 (20 mg kg 21 , DOCA-GW20). Data presented as a ratio of arbitrary units of mRNA (2 2DDCt ) or densitometric values of protein band normalized to the corresponding a-actin, compared with the control-vehicle group. The results of western blots are shown as mean + SEM, derived from four to six separate rings from different rats.
# P , 0.05 and ## P , 0.01 when compared with the control group, respectively. *P , 0.05 and **P , 0.01 when compared with the DOCA group, respectively. PPARb agonist in DOCA-salt hypertension wall, which increased RGS5 expression, with the subsequent interference with ET-1 signalling, leading to reduced contractile response to ET-1 and intracellular ROS generation. Moreover, the activation of PPARb up-regulated antioxidant genes, including Cu/Zn-SOD, Mn-SOD, catalase, GPx1, and HO-1.
Our previous study demonstrates that GW0742, at 5 mg kg 21 exerted antihypertensive effects, partly restored the vascular structure and function, and reduced the oxidative, proinflammatory, and proatherogenic status of SHR. These protective effects seem to be related to increased expression of RGS4 and RGS5, which negatively modulated the vascular actions of Ang II. 27 In the present study we also show a clear dissociation between high blood pressure and endothelial function, since GW0742 at 5 mg kg 21 prevented the raise in SBP ( 61%) but had no effect on the endothelial function. Similar results have been previously described for the PPARa agonist fenofibrate.
14 Moreover, the antihypertensive effect induced by GW0742 seems to be independent of PPARb activation, since it was unaffected by the PPARb antagonist GSK0660. PPARa and PPARg activators prevent the raise in SBP in DOCA-salt rats by inhibition of ppET-1 mRNA production.
14 This agrees with the blood pressure-lowering effects of selective ET receptor blockers and with the notion that ET-1 participates in the pathophysiology of this model of hypertension. 32 However, GW0742 was unable to reduce vascular ppET-1 mRNA and plasma ET-1 levels. Paradoxically, GW0742 at 20 mg kg 21 increased ppET-1 mRNA in DOCA-salt rats, but reduced the expression of ECE1, the enzyme converting pro-ET-1 into ET-1, which could collaborate to maintain similar ET-1 plasma levels. The raise in ppET-1 mRNA induced by GW0742 was unaltered by PPARb blockade, showing that the expression of this gene is PPARb independent.
The expression of PPAR in the aorta was increased in DOCA-salt rats (present results) and in SHR 27 when compared with control rats, and chronic treatment with GW0742 reversed these changes. The expression of PPARb is modulated by oxidative stress and inflammation. Jiang et al. 33 have shown that in human umbilical vein endothelial cells, repetitive low grade of H 2 O 2 stress enhances PPARb expression while Tan et al. 34 found increased PPARb in keratinocytes by another pro-oxidant stimulus TNFa. Therefore, we speculate that in the DOCA salt rats the up-regulation of aortic PPARb may be due to the increased H 2 O 2 content. Conversely, GW0742 via a reduction in the vascular H 2 O 2 content in the DOCA-salt animals may restore the expression of PPARb. As expected, GW0742 induced, in a concentration-dependent manner, an increased expression of PPARb-target gene PDK4 in the aorta, which was abolished by GSK0660, confirming that chronic GW0742-activated PPARb in the vasculature. Moreover, the PPARb agonist increased CD36 expression which is expected to increase the uptake of the endogenous PPARb ligands, e.g. fatty acids. DOCA-salt rat showed a reduced contractile response to ET-1, which may act as a compensatory mechanism to the increased vascular resistance and blood pressure during DOCA-salt hypertension. This reduced response to ET-1 has been explained in the literature by (i) decreased density of ET A receptors, (ii) reduced increment of intracellular calcium concentration to ET-1, and (iii) reduced activation of p38 MAPK to ET-1 with the subsequent diminished caldesmon phosphorylation. 35 In our experiments, the mRNA level of ET A receptor was similar in all experimental groups suggesting downstream changes to explain the reduced response to ET-1 found in DOCA-salt rats. RGS proteins play important roles in the regulation of G protein-coupled receptor signalling by binding to the active G subunits and stimulating GTP hydrolysis, thus switching off G protein signalling. 28 Thus, RGS down-regulation potentiates the effect of vasoconstrictors like endothelin and Ang II.
36
RGS5 exhibits a striking expression pattern in vascular smooth muscle cells and is a potent GTPase-activating factor for a number of Gia-and Gqa-mediated pathways, including those of Ang II and endothelin 1, suggesting a role in blood pressure regulation. 37 Genome-wide linkage and candidate gene-based association studies have identified the human RGS5 gene as one of the three genes that contribute to elevated blood pressure in human. 38 Very recently, down-regulation of RGS5 was sufficient to cause enhanced myogenic constriction in intact resistance arteries, which is essential in the regulation of blood flow and provides the basal tone in resistance arteries. 29 Similarly, overexpression studies in the aorta showed that RGS5 inhibits contractions via Gqa. 27, 39 Paradoxically, in our study, the mRNA expression of RGS5 was down-regulated in DOCA-salt rats. Therefore, reduced contractile responses to ET-1 cannot be attributed to changes in RGS5. RGS5 is a direct gene target of PPARb. 29 Likewise, we found that GW0742 at 20 mg kg 21 induced an increase in RGS5 expression in the aorta from the control and DOCA-salt rats, which was suppressed by PPARb blockade, without changes in the ET A receptor expression. This increase in RGS5 would reduce ET A receptor signalling and hence ET-1-induced vasoconstriction. In fact, GW0742 at 20 mg kg 21 reduced the ET-1 contraction in both control and DOCA-salt rats, whereas GW0742 at 5 mg kg 21 had no effect on either RGS5 expression or ET-1 contractility.
ET-1 has been involved in the development of vascular oxidative stress and endothelial dysfunction in DOCA-salt rats since ET A receptor blockade reduced arterial O 2 †2 levels with a concomitant improvement in endothelium-dependent relaxation. 10 In DOCA-salt rats, we also found impaired endothelium-dependent vasodilator responses, decreased plasma levels of NOx, increased plasma levels of ET-1 and MDA, increased urinary isoprostanes excretion, and a higher content of aortic ROS. It is well established that ET-1 activates NADPH oxidase to produce vascular O 2 †2 generation in DOCA-salt hypertensive rats via up-regulation of the NADPH oxidase subunits 5, 6, 10, 40 PPARb agonist in DOCA-salt hypertension (present study). In this paper, GW0742 at 20 mg kg 21 reduced the increased aortic intracellular ROS content, NADPH oxidase activity, up-regulation of NOX4, and the impaired acetylcholine-induced relaxation. We also found that the main H 2 O 2 detoxifying enzyme catalase was significantly down-regulated in the aorta from DOCA-salt rats, which may also account for the higher staining of the peroxide-sensitive dye DCF. The chronic treatment of the control rats with GW0742-induced transcriptional up-regulation of antioxidant genes HO-1 and GPx1, as previously reported by PPARb activation in cultured vascular smooth muscle cell. 41 Moreover, GW0742 also up-regulated other PPARb-sensitive antioxidant genes, such as Cu/Zn-SOD, 42 Mn-SOD, 41 and catalase 42 in DOCA-salt rats, contributing to detoxify intracellular ROS. Collectively, all these data indicate that the improvement of endothelial dysfunction induced by PPARb activation seems to be related to increased NO bioactivity by reducing NADPH oxidasedriven O 2 †2 production stimulated by ET-1 in aortic rings and by increasing antioxidant defences. Other mechanisms might also contribute, including a possible increased NO synthesis as a result of a decrease in the negative allosteric regulator of eNOS, caveolin-1, and an increased sensitivity, to the NO-cGMP pathway, as demonstrated by small increase in nitroprusside relaxation induced by GW0742 in the DOCAsalt rats.
All these data suggest that up-regulation of RGS5 may be an essential step in the effects of the PPARb agonist described herein including its antihypertensive, antioxidant actions, and protective effect in the endothelial function. However, the dose of 5 mg kg 21 GW0742 was unable to up-regulate RGS5 in the DOCA-salt rats, which suggests the involvement of additional mechanisms independent of ET-1 synthesis and signalling. Acute non-genomic vasodilator effects of GW0742 have also been described in the rat aorta 43 and in mice vessels. 44 The vasodilator response in the rat aorta was partially prevented by the PPARb antagonist GSK0660 43 and was reduced in the aorta but not in pulmonary or mesenteric vessels from PPARb2/2 when compared with wild-type mice. 44 Herein we also found that in rat small mesenteric arteries, as in mice mesenteric arteries, GW0742 induced a concentrationdependent relaxant response which was independent of PPARb activation, because it was unaffected by the PPARb antagonist GSK0660. This effect, which was also independent of endothelial NO release, since it was unaltered by eNOS inhibition, may also collaborate to reduce SBP.
In conclusion, our results clearly demonstrate that the PPARb agonist GW0742 reduces the increase in blood pressure, and at the higher dose of 20 mg kg 21 improves the cardiac hypertrophy, the endothelial dysfunction, and the vascular oxidative stress in this model of mineralocorticoid-induced hypertension. These effects on the endothelial function seem to be related to PPARb activation via reduced NADPH-oxidase-mediated O 2 †2 production stimulated by ET-1, up-regulation of RGS5, and increased antioxidant enzymatic defences, finally resulting in increased NO bioactivity.
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